Your browser is no longer supported. Please, upgrade your browser.
Settings
DMAC DiaMedica Therapeutics Inc. daily Stock Chart
DMAC [NASD]
DiaMedica Therapeutics Inc.
Index- P/E- EPS (ttm)-0.92 Insider Own8.37% Shs Outstand11.96M Perf Week-19.96%
Market Cap43.64M Forward P/E- EPS next Y- Insider Trans- Shs Float9.07M Perf Month-4.45%
Income- PEG- EPS next Q- Inst Own13.72% Short Float0.77% Perf Quarter-7.59%
Sales0.50M P/S87.29 EPS this Y- Inst Trans- Short Ratio0.59 Perf Half Y2.67%
Book/sh1.16 P/B3.14 EPS next Y- ROA- Target Price- Perf Year-68.91%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range2.46 - 11.80 Perf YTD25.43%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-69.07% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low48.37% ATR0.46
Employees9 Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)41.97 Volatility10.85% 11.36%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.57 Prev Close3.91
ShortableYes LT Debt/Eq- EarningsAug 12 AMC Payout- Avg Volume117.42K Price3.65
Recom- SMA20-19.72% SMA500.40% SMA200-15.28% Volume66,522 Change-6.65%
Apr-30-19Initiated Dougherty & Company Buy $8
Mar-05-19Initiated Lake Street Buy $9
Jun-21-19 07:18AM  The Daily Biotech Pulse: ContraVir's Volatile Ride Continues, Late-Stage Disappointment For Exelixis, Regeneron-Sanofi Breathe Easy Benzinga -6.07%
Jun-20-19 07:25AM  The Daily Biotech Pulse: DiaMedica Reports Positive Data For Chronic Kidney Disease Drug, Eloxx Offering, IPO Deluge Benzinga +29.32%
Jun-19-19 04:04PM  DiaMedica Therapeutics Announces Interim Results from Phase 1b Trial of DM199 in Chronic Kidney Disease Participants GlobeNewswire
May-21-19 08:34AM  DiaMedica Therapeutics Announces Formation of Scientific Advisory Board for Kidney Disease GlobeNewswire
May-14-19 06:00AM  DiaMedica Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
May-13-19 04:48PM  DiaMedica Therapeutics Announces First Quarter 2019 Financial Results and Provides Business Update GlobeNewswire -5.36%
May-06-19 08:54AM  DiaMedica Therapeutics to Report First Quarter 2019 Financials and Provide an Update on Development Programs on May 14, 2019 GlobeNewswire
Apr-30-19 04:58PM  DiaMedica Therapeutics to Present at CKD3 Kidney Summit Meeting GlobeNewswire
Mar-19-19 04:30PM  DiaMedica Therapeutics Announces 2018 Financial Results and Provides Corporate Update GlobeNewswire
Mar-18-19 01:56PM  DiaMedica Therapeutics Announces Date for the Release of Full Year 2018 Results and Conference Call GlobeNewswire
Mar-12-19 01:00PM  DiaMedica Therapeutics to Attend 31st Annual ROTH Investor Conference on March 18-19, 2019 GlobeNewswire
Feb-14-19 08:00AM  DiaMedica Therapeutics Doses First Patient in Phase 1b Clinical Study of DM199 in Patients with Chronic Kidney Disease GlobeNewswire
Jan-22-19 07:45AM  DiaMedica Therapeutics Announces Publication of a Paper, Human Tissue Kallikrein in the Treatment of Acute Ischemic Stroke, in the Journal Therapeutic Advances in Neurological Disorders GlobeNewswire
Jan-16-19 04:00PM  OTC Markets Group Announces Quarterly Index Performance and Rebalancing PR Newswire
Jan-10-19 08:27AM  The Daily Biotech Pulse: Cancer Genetics Prices Offering, DiaMedica Delists From Canadian Exchange, Medigus CEO Quits Benzinga
Jan-09-19 05:00PM  DiaMedica Therapeutics Announces Voluntary Delisting from TSX Venture Exchange GlobeNewswire
Jan-03-19 10:41AM  UPDATE - DiaMedica Announces FDA Clearance of IND Application To Study DM199 in Patients with Chronic Kidney Disease GlobeNewswire
Dec-02-18 05:01PM  IPO Outlook For The Week: Proteins, Fashion And Finance Benzinga
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of recombinant proteins for the treatment of kidney and neurological diseases. Its lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase Ib clinical trials for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase II REMEDY trials for the treatment of patients with acute ischemic stroke. The company is also developing DM199 for the treatment vascular dementia; and DMDx, a diagnostic tool to measure human tissue kallikrein-1 levels. It has a license and collaboration agreement with Ahon Pharmaceutical Co Ltd. to develop and commercialize DM199 for acute ischemic stroke. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.